image
Healthcare - Biotechnology - NASDAQ - US
$ 2.36
8.76 %
$ 326 M
Market Cap
-5.9
P/E
1. INTRINSIC VALUE

This DCF valuation model was last updated on May, 22, 2025.

The intrinsic value of one CMPX stock under the worst case scenario is HIDDEN Compared to the current market price of 2.36 USD, Compass Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on May, 22, 2025.

The intrinsic value of one CMPX stock under the base case scenario is HIDDEN Compared to the current market price of 2.36 USD, Compass Therapeutics, Inc. is HIDDEN

This DCF valuation model was last updated on May, 22, 2025.

The intrinsic value of one CMPX stock under the best case scenario is HIDDEN Compared to the current market price of 2.36 USD, Compass Therapeutics, Inc. is HIDDEN

2. FUNDAMENTAL ANALYSIS

Price Chart CMPX

image
$4.0$4.0$3.5$3.5$3.0$3.0$2.5$2.5$2.0$2.0$1.5$1.5$1.0$1.0Dec '24Dec '2420252025Feb '25Feb '25Mar '25Mar '25Apr '25Apr '25May '25May '25Jun '25Jun '25
FINANCIALS
0 REVENUE
0.00%
-50.4 M OPERATING INCOME
-20.91%
-42.5 M NET INCOME
-8.33%
-40.6 M OPERATING CASH FLOW
-19.03%
27 M INVESTING CASH FLOW
117.83%
2.94 M FINANCING CASH FLOW
-96.13%
0 REVENUE
0.00%
-12.2 M OPERATING INCOME
18.65%
-10.5 M NET INCOME
19.86%
-11.1 M OPERATING CASH FLOW
-2.76%
29 M INVESTING CASH FLOW
347.60%
-2 K FINANCING CASH FLOW
-200.00%
Balance Sheet Compass Therapeutics, Inc.
image
Current Assets 154 M
Cash & Short-Term Investments 152 M
Receivables 0
Other Current Assets 1.42 M
Non-Current Assets 2.99 M
Long-Term Investments 0
PP&E 2.67 M
Other Non-Current Assets 320 K
97.19 %Total Assets$156.9m
Current Liabilities 7.8 M
Accounts Payable 4.09 M
Short-Term Debt 1.2 M
Other Current Liabilities 2.51 M
Non-Current Liabilities 536 K
Long-Term Debt 536 K
Other Non-Current Liabilities 0
49.06 %14.36 %30.15 %6.43 %Total Liabilities$8.3m
EFFICIENCY
Earnings Waterfall Compass Therapeutics, Inc.
image
Revenue 0
Cost Of Revenue 1.89 M
Gross Profit -1.89 M
Operating Expenses 48.5 M
Operating Income -50.4 M
Other Expenses -7.87 M
Net Income -42.5 M
00(10m)(10m)(20m)(20m)(30m)(30m)(40m)(40m)(50m)(50m)(60m)(60m)0(2m)(2m)(48m)(50m)8m(42m)RevenueRevenueCost Of RevenueCost Of RevenueGross ProfitGross ProfitOperating ExpensesOperating ExpensesOperating IncomeOperating IncomeOther ExpensesOther ExpensesNet IncomeNet Income
RATIOS
0.00% GROSS MARGIN
0.00%
0.00% OPERATING MARGIN
0.00%
0.00% NET MARGIN
0.00%
-28.61% ROE
-28.61%
-27.09% ROA
-27.09%
-33.51% ROIC
-33.51%
FREE CASH FLOW ANALYSIS
Free Cash Flow Analysis Compass Therapeutics, Inc.
image
00(5m)(5m)(10m)(10m)(15m)(15m)(20m)(20m)(25m)(25m)(30m)(30m)(35m)(35m)(40m)(40m)(45m)(45m)Jul '19Jul '1920202020Jul '20Jul '2020212021Jul '21Jul '2120222022Jul '22Jul '2220232023Jul '23Jul '2320242024
Net Income -42.5 M
Depreciation & Amortization 1.89 M
Capital Expenditures -30 K
Stock-Based Compensation 6.12 M
Change in Working Capital -2.91 M
Others 2.35 M
Free Cash Flow -40.6 M
3. WALL STREET ANALYSTS ESTIMATES
Wall Street Analysts Price Targets Compass Therapeutics, Inc.
image
Wall Street analysts predict an average 1-year price target for CMPX of $5.5 , with forecasts ranging from a low of $5 to a high of $6 .
CMPX Lowest Price Target Wall Street Target
5 USD 111.86%
CMPX Average Price Target Wall Street Target
5.5 USD 133.05%
CMPX Highest Price Target Wall Street Target
6 USD 154.24%
Price
Max Price Target
Min Price Target
Average Price Target
66554433221100Jul '24Jul '24Aug '24Aug '24Oct '24Oct '24Nov '24Nov '2420252025Feb '25Feb '25Apr '25Apr '25Jun '25Jun '25Jul '25Jul '25Aug '25Aug '25Oct '25Oct '25Nov '25Nov '2520262026Feb '26Feb '26Apr '26Apr '26Jun '26Jun '26
4. DIVIDEND ANALYSIS
5. COMPETITION
slide 2 of 20
6. Ownership
Insider Ownership Compass Therapeutics, Inc.
image
Sold
0-3 MONTHS
11.4 M USD 2
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
0 USD 0
Bought
59.2 K USD 2
0-3 MONTHS
0 USD 0
3-6 MONTHS
0 USD 0
6-9 MONTHS
0 USD 0
9-12 MONTHS
7. News
Compass Therapeutics: A Big Positive Signal For Tovecimig In Biliary Tract Cancers Compass Therapeutics' tovecimig shows promise in biliary tract cancer with a 17.1% response rate, but further survival data is crucial for potential approval. CMPX's cash runway extends into early 2027, providing financial stability to reach key milestones and possibly raise funds from a stronger position. Other pipeline candidates, CTX-471 and CTX-8371, have upcoming trials and readouts in 2025, adding potential value to CMPX's portfolio. seekingalpha.com - 1 month ago
Compass Therapeutics Reports 2025 First Quarter Financial Results and Provides Corporate Update Tovecimig (DLL4 x VEGF-A bispecific antibody) met the primary endpoint in the ongoing randomized Phase 2/3 Study in patients with biliary tract cancer (BTC). Achieved a 17.1% overall response rate (ORR), including one complete response, compared to a 5.3% ORR for paclitaxel alone, in patients with BTC treated in the second-line setting. globenewswire.com - 1 month ago
Compass Therapeutics to Participate in Upcoming May Investor Events BOSTON, May 06, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, today announced that the Company will participate in the following investor events during the month of May. Details are as follows: The Citizens Life Sciences Conference Location: New York, NY Date: Thursday, May 8, 2025 Time: 1:30 PM ET Webcast Link: https://wsw.com/webcast/jmp65/cmpx/1692592 H.C. globenewswire.com - 1 month ago
Compass Therapeutics Presents Data on Enhanced Efficacy of CTX-471 in Combination with Tovecimig in Checkpoint-Refractory Models at the American Association for Cancer Research (AACR) Annual Meeting CTX-471 monotherapy demonstrated efficacy in multiple murine models, including models highly resistant to immune checkpoint inhibitors. Combining CTX-471 with tovecimig (CTX-009) markedly increased anti-tumor efficacy in these models. globenewswire.com - 1 month ago
2 Penny stocks to buy in May 2025 Summary ⚈ Market conditions in May create opportunities for penny stock investors.⚈ Compass Therapeutics and Blade Air Mobility are highlighted for strong growth prospects. finbold.com - 1 month ago
Compass Therapeutics Announces First Patient Dosed in an Investigator Sponsored Trial of Tovecimig in the First-Line Setting for Patients with Biliary Tract Cancer BOSTON, April 21, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics, announced the first patient has been dosed in an Investigator Sponsored Trial (IST) to evaluate tovecimig (CTX-009, a DLL4 x VEGF-A bispecific antibody) for the first time in the front-line setting for patients with biliary tract cancer (BTC). The IST is being conducted at The University of Texas MD Anderson Cancer Center. globenewswire.com - 1 month ago
Compass Therapeutics to Participate in the Stifel 2025 Virtual Targeted Oncology Forum BOSTON, April 02, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, today announced that the Company will present at the Stifel 2025 Virtual Targeted Oncology Forum taking place April 8-9, 2025. globenewswire.com - 2 months ago
Tovecimig (CTX-009) Meets Primary Endpoint in the Ongoing Randomized Phase 2/3 Study in Patients with Biliary Tract Cancer Tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel achieved a 17.1% overall response rate (ORR), including one complete response, compared to 5.3% ORR for paclitaxel alone, in patients with biliary tract cancer (BTC) treated in the second-line setting. The difference in ORR between the two treatment arms, the primary endpoint of the study, was statistically significant (p=0.031), and all responses have been confirmed by blinded independent central radiology review. globenewswire.com - 2 months ago
Compass Therapeutics to Host Webcast Highlighting Top-Line Clinical Data from the Ongoing Randomized Phase 2/3 Study Evaluating Tovecimig in Patients with Biliary Tract Cancer Webcast scheduled for Tuesday, April 1, 2025 at 8:00 AM ET. BOSTON, March 31, 2025 (GLOBE NEWSWIRE) -- Compass Therapeutics, Inc. (Nasdaq: CMPX), a clinical-stage, oncology-focused biopharmaceutical company developing proprietary antibody-based therapeutics to treat multiple human diseases, announced it will host a webcast on Tuesday, April 1, 2025 at 8:00 AM ET to review top-line clinical data from its ongoing Phase 2/3 COMPANION-002 clinical trial assessing tovecimig (a DLL4 x VEGF-A bispecific antibody) in combination with paclitaxel in patients with advanced biliary tract cancer (BTC). globenewswire.com - 2 months ago
Compass Therapeutics Reports 2024 Financial Results and Provides Corporate Update Top-line Phase 2/3 data readout for COMPANION-002, evaluating tovecimig (CTX-009 - a DLL4 x VEGF-A bispecific antibody) in patients with biliary tract cancer (BTC), is on track for the end of the first quarter 2025. Supported initiation of an Investigator Sponsored Study (IST) evaluating tovecimig in patients with BTC in the first-line setting, with patient dosing expected in the first quarter 2025. globenewswire.com - 3 months ago
Compass Therapeutics, Inc. (CMPX) Upgraded to Buy: What Does It Mean for the Stock? Compass Therapeutics, Inc. (CMPX) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). zacks.com - 4 months ago
Top 3 High-Momentum Companies Analysts Are Still Bullish On The principle of momentum investing—though contrary to the traditional wisdom of buying low and selling high—suggests that investors can profit by buying rising stocks and selling them before they decline. As a result, momentum is typically favored in short-term and active trading strategies rather than long-term investing. marketbeat.com - 4 months ago
8. Profile Summary

Compass Therapeutics, Inc. CMPX

image
COUNTRY US
INDUSTRY Biotechnology
MARKET CAP $ 326 M
Dividend Yield 0.00%
Description Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137. Its product candidates also comprise CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1. The company was founded in 2014 and is headquartered in Boston, Massachusetts.
Contact 80 Guest Street, Boston, MA, 02135 https://www.compasstherapeutics.com
IPO Date April 5, 2021
Employees 35
Officers Mr. Neil L. Lerner CPA Senior Vice President & Chief Accounting Officer Dr. Thomas J. Schuetz M.D., Ph.D. Chief Executive Officer & Vice Chairman Ms. Karin Herrera B.A. Senior Vice President & Head of Clinical Operations Anna Gifford Communications Manager Dr. James Kranz Ph.D. Vice President and Head of Chemistry Manufacturing & Controls Ms. Vered Bisker-Leib MBA, Ph.D. Advisor Mr. Barry Shin J.D., M.B.A. Chief Financial Officer Dr. Minori Rosales M.D., Ph.D. Senior Vice President & Head of Clinical Development Mr. Jonathan E. Anderman J.D. Senior Vice President, General Counsel & Corporate Secretary